

# Antonella Giannantoni Ag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/698700/publications.pdf>

Version: 2024-02-01

55  
papers

1,966  
citations

331670

21  
h-index

243625

44  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1525  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Regarding the diagnosis of detrusor underactivity in: "Urodynamics criteria of detrusor underactivity in women underwent middle urethral sling for stress urinary incontinence: What is the clinical role? <i>Neurourol Urodyn</i> 2021. August 22. doi.org/10.1002/nau.24773" <i>Neurourology and Urodynamics</i> , 2022, 41, 508-509. | 1.5 | 0         |
| 2  | IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. <i>Minerva Urology and Nephrology</i> , 2022, 74, .   | 2.5 | 2         |
| 3  | Can urethral re-bulking improve the outcomes of a prior urethral bulking?. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722110692.  | 2.0 | 1         |
| 4  | The International Female Coital Incontinence Questionnaire (IFCI-Q): Development, Validation and Reliability Study. <i>Journal of Sexual Medicine</i> , 2022, 19, 158-163.  | 0.6 | 3         |
| 5  | Urethral Bulking in the Treatment of Stress and Mixed Female Urinary Incontinence: Results from a Multicenter Cohort and Predictors of Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 1569.   | 2.4 | 5         |
| 6  | Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). <i>European Urology</i> , 2022, 82, 223-232.  | 1.9 | 17        |
| 7  | Increased risk of transurethral and suprapubic catheter self-extraction in COVID-19 patients: real-life experience. <i>British Journal of Nursing</i> , 2022, 31, S24-S30.  | 0.7 | 0         |
| 8  | The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer. <i>Cancers</i> , 2022, 14, 3118.  | 3.7 | 2         |
| 9  | AUTHOR REPLY. <i>Urology</i> , 2021, 148, 46.   | 1.0 | 0         |
| 10 | Continuing care for patients affected by urologic chronic pelvic pain in the era of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. <i>Neurourology and Urodynamics</i> , 2021, 40, 397-403.   | 1.5 | 5         |
| 11 | The Role of Emotional Condition in Patients With Lower Urinary Tract Symptoms Performing Uroflowmetry. <i>Urology</i> , 2021, 148, 37-46.   | 1.0 | 3         |
| 12 | Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy. <i>Ochsner Journal</i> , 2021, 21, 301-305.  | 1.1 | 0         |
| 13 | Resilience in the face of pelvic pain: A pilot study in males and females affected by urologic chronic pelvic pain. <i>Neurourology and Urodynamics</i> , 2021, 40, 1011-1020.  | 1.5 | 5         |
| 14 | Urodynamics criteria of detrusor underactivity in women underwent middle urethral sling for stress urinary incontinence: What is the clinical role?. <i>Neurourology and Urodynamics</i> , 2021, 40, 1955-1965.   | 1.5 | 3         |
| 15 | Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 5989.  | 3.7 | 11        |
| 16 | Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 445-449.  | 0.8 | 1         |
| 17 | Nocturia and Nocturnal Polyuria in Neurological Patients: From Epidemiology to Treatment. A Systematic Review of the Literature. <i>European Urology Focus</i> , 2020, 6, 922-934.  | 3.1 | 16        |
| 18 | Triage of functional, female and neuro-urology patients during and immediately after the Covid-19 outbreak. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 513-515.   | 3.9 | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Bladder and bowel dysfunction, adaptive behaviour and psychiatric profiles in adults affected by autism spectrum disorders. <i>Neurourology and Urodynamics</i> , 2019, 38, 1866-1873.  | 1.5 | 6         |
| 20 | Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis. <i>Toxins</i> , 2019, 11, 510.  | 3.4 | 17        |
| 21 | The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. <i>BMC Urology</i> , 2019, 19, 7.  | 1.4 | 7         |
| 22 | Urodynamic findings and functional outcomes after laparoscopic sacrocolpopexy for symptomatic pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2019, 30, 589-594.  | 1.4 | 12        |
| 23 | Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: A pilot study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984345.   | 3.5 | 16        |
| 24 | <i>Serenoa repens</i> + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). <i>BJU International</i> , 2018, 122, 317-325. | 2.5 | 10        |
| 25 | Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. <i>Neurourology and Urodynamics</i> , 2018, 37, 904-915.   | 1.5 | 6         |
| 26 | A practical approach to the management of nocturia. <i>International Journal of Clinical Practice</i> , 2017, 71, e13027.   | 1.7 | 76        |
| 27 | Association between selenium and lycopene supplementation and incidence of prostate cancer: Results from the post-hoc analysis of the procomb trial. <i>Phytomedicine</i> , 2017, 34, 1-5.  | 5.3 | 26        |
| 28 | Long-term efficacy of the trans-obturator and retropubic mid-urethral slings for stress urinary incontinence: update from a randomized clinical trial. <i>World Journal of Urology</i> , 2016, 34, 585-593.   | 2.2 | 43        |
| 29 | Chronic prostatitis: how to give our best without apposite vagueness. <i>BJU International</i> , 2015, 116, 499-500.  | 2.5 | 2         |
| 30 | OnabotulinumtoxinA Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management. <i>Urologia</i> , 2015, 82, 179-183.  | 0.7 | 10        |
| 31 | Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. <i>Toxins</i> , 2015, 7, 3424-3435.   | 3.4 | 5         |
| 32 | OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. <i>World Journal of Urology</i> , 2015, 33, 2095-2101.   | 2.2 | 23        |
| 33 | Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non-muscle invasive bladder cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, e15544-e15544.   | 1.6 | 0         |
| 34 | Urodynamic Evaluation after High-Intensity Focused Ultrasound for Patients with Prostate Cancer. <i>Prostate Cancer</i> , 2014, 2014, 1-7.  | 0.6 | 6         |
| 35 | An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders. <i>European Urology</i> , 2014, 65, 981-990.   | 1.9 | 148       |
| 36 | Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. <i>Chemico-Biological Interactions</i> , 2014, 224, 128-135.   | 4.0 | 12        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The Efficacy and Safety of Duloxetine in a Multidrug Regimen for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. <i>Urology</i> , 2014, 83, 400-405.   | 1.0 | 30        |
| 38 | Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. <i>Pharmacological Research</i> , 2013, 68, 118-124.                 | 7.1 | 29        |
| 39 | Contemporary Management of the Painful Bladder: A Systematic Review. <i>European Urology</i> , 2012, 61, 29-53.  | 1.9 | 104       |
| 40 | Urologic Dysfunction and Neurologic Outcome in Coma Survivors After Severe Traumatic Brain Injury in the Postacute and Chronic Phase. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011, 92, 1134-1138. | 0.9 | 28        |
| 41 | Botulinum Toxin Type A in Patients With Parkinson's Disease and Refractory Overactive Bladder. <i>Journal of Urology</i> , 2011, 186, 960-964.   | 0.4 | 98        |
| 42 | Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome. <i>Current Drug Delivery</i> , 2010, 7, 1-4.                                 | 1.6 | 33        |
| 43 | Botulinum A Toxin Intravesical Injections for Painful Bladder Syndrome: Impact Upon Pain, Psychological Functioning and Quality of Life. <i>Current Drug Delivery</i> , 2010, 7, 442-446.                            | 1.6 | 33        |
| 44 | Six-Year Follow-Up of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity: Clinical and Urodynamic Results. <i>European Urology</i> , 2009, 55, 705-712.      | 1.9 | 132       |
| 45 | Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson's Disease and Multiple System Atrophy. <i>Journal of Urology</i> , 2009, 182, 1453-1457.                        | 0.4 | 124       |
| 46 | Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. <i>BJU International</i> , 2008, 102, 2-6.  | 2.5 | 15        |
| 47 | Bladder and Urethral Sphincter Function after Radical Retropubic Prostatectomy: A Prospective Long-Term Study. <i>European Urology</i> , 2008, 54, 657-664.  | 1.9 | 82        |
| 48 | Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year Followup. <i>Journal of Urology</i> , 2008, 179, 1031-1034.   | 0.4 | 137       |
| 49 | Botulinum-A Toxin Injections Into the Detrusor Muscle Decrease Nerve Growth Factor Bladder Tissue Levels in Patients With Neurogenic Detrusor Overactivity. <i>Journal of Urology</i> , 2006, 175, 2341-2344.        | 0.4 | 139       |
| 50 | Botulinum A Toxin Intravesical Injections in the Treatment of Painful Bladder Syndrome: A Pilot Study. <i>European Urology</i> , 2006, 49, 704-709.  | 1.9 | 120       |
| 51 | New Frontiers in Intravesical Therapies and Drug Delivery. <i>European Urology</i> , 2006, 50, 1183-1193.  | 1.9 | 101       |
| 52 | ASSESSMENT OF BLADDER AND URETHRAL SPHINCTER FUNCTION BEFORE AND AFTER RADICAL RETROPUBIC PROSTATECTOMY. <i>Journal of Urology</i> , 2004, 171, 1563-1566.   | 0.4 | 78        |
| 53 | INTRAVESICAL RESINIFERATOXIN VERSUS BOTULINUM-A TOXIN INJECTIONS FOR NEUROGENIC DETRUSOR OVERACTIVITY: A PROSPECTIVE RANDOMIZED STUDY. <i>Journal of Urology</i> , 2004, 172, 240-243.                               | 0.4 | 140       |
| 54 | Pelvic Floor Muscle Behavior During Valsalva Leak Point Pressure Measurement in Males and Females Affected by Stress Urinary Incontinence. <i>Journal of Urology</i> , 2003, 170, 485-489.                           | 0.4 | 17        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. Journal of Urology, 2002, 167, 1710-4. | 0.4 | 21        |